Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
